Checkpoint Inhibitor Refractory Cancer Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2023-2032), Analyzes DelveInsight | Checkmate Pharma, BIOCAD, 3D Medicines, OncoSec

Checkpoint Inhibitor Refractory Cancer Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2023-2032), Analyzes DelveInsight | Checkmate Pharma, BIOCAD, 3D Medicines, OncoSec
DelveInsight’s “Checkpoint Inhibitor Refractory Cancer Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Checkpoint Inhibitor Refractory Cancer.

DelveInsight’s “Checkpoint Inhibitor Refractory Cancer Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Checkpoint Inhibitor Refractory Cancer, historical and forecasted epidemiology as well as the Checkpoint Inhibitor Refractory Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Checkpoint Inhibitor Refractory Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Checkpoint Inhibitor Refractory Cancer Market Forecast

 

Some of the key facts of the Checkpoint Inhibitor Refractory Cancer Market Report: 

  • The Checkpoint Inhibitor Refractory Cancer market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • In April 2023, BeiGene and Enlivex Therapeutics Ltd. have announced a clinical collaboration. The objective of the Company’s Phase I/II clinical trial, which is currently underway, is to assess the safety and efficacy of Allocetra, an investigational macrophage-reprogramming cell therapy, in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor, for the treatment of patients with advanced-stage solid tumours
  • In January 2023, AB011, the first humanised monoclonal antibody against Claudin18.2 (CLDN18.2) to receive global IND clearance, and atezolizumab, Roche’s PD-L1 checkpoint inhibitor, will be tested in combination with standard-of-care chemotherapy in patients with gastric or gastroesophageal junction carcinoma, according to a statement from CARsgen Therapeutics Holdings Limited. According to the terms of the arrangement, Roche will be in charge of managing the trial’s administration, while both businesses will split the expense of the study’s AB011 treatment arms
  • In 2021, there were 158,436 individuals who received treatment for 7MM incident cases of checkpoint inhibitor-resistant infections, with the majority of those cases occurring in the US. There were 64,487 cases in the EU5 nations in 2021.In 2021, Japan had 29,362 instances. By aggregating the cases in various nations, the total incident cases of checkpoint-inhibitor treated patients in 7MM is calculated
  • NSCLC had the highest incidence in the US in 2021, with 197,496 cases, and it is predicted that number will rise to 242,279 cases by 2032. Merkel cell carcinoma has the fewest cases (2,646 instances), although that number is expected to rise to 2,845 cases by 2032
  • Merkel cell cancer has the lowest rate of Checkpoint-Inhibitor refractory cases, with 106 cases in the US in 2021 and a projected increase to 114 cases by 2032.
  • Key Checkpoint Inhibitor Refractory Cancer Companies: OncoSec Medical, CatalYm, BerGenBio, Checkmate Pharmaceuticals, BIOCAD, 3D Medicines, Innovent Biologics, EMD Serono/Merck, Aurigene Discovery Technologies, CanBas Co., Ltd, Agenu, Laekna Therapeutics, BeBetter Med, Hangzhou Sumgen Biotech, Harbour BioMed, Phio Pharmaceuticals, and others
  • Key Checkpoint Inhibitor Refractory Cancer Therapies: Tavo + Pembrolizumab, CTL-002, Bemcentinib + Pembrolizumab, CMP-001 + Nivolumab, BCD-100, Envafolimab, IBI310, Bintrafusp alfa, CA-170, CBP501, Botensilimab, FAZ053, BEBT-260, SG 12473, HBM-9027, PH-3861, and others
  • The American Cancer Society estimates that in the US in 2021, there will be roughly 106,110 new cases of melanomas, out of which 7,180 individuals are projected to die. Over the past few decades, melanoma rates have been sharply increasing
  • The Checkpoint Inhibitor Refractory Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Checkpoint Inhibitor Refractory Cancer pipeline products will significantly revolutionize the Checkpoint Inhibitor Refractory Cancer market dynamics.

 

Checkpoint Inhibitor Refractory Cancer Overview

Drugs that block immunological checkpoints are known as immune checkpoint inhibitors. These medications enable immune cells to react to cancer more forcefully by inhibiting them. As a result, the T-cells are able to destroy cancer cells because the “off”signal is not sent.

 

Get a Free sample for the Checkpoint Inhibitor Refractory Cancer Market Report 

https://www.delveinsight.com/report-store/checkpoint-inhibitor-refractory-cancer-market

 

Checkpoint Inhibitor Refractory Cancer Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Checkpoint Inhibitor Refractory Cancer Epidemiology Segmentation:

The Checkpoint Inhibitor Refractory Cancer market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Checkpoint Inhibitor Refractory Cancer
  • Prevalent Cases of Checkpoint Inhibitor Refractory Cancer by severity
  • Gender-specific Prevalence of Checkpoint Inhibitor Refractory Cancer
  • Diagnosed Cases of Episodic and Chronic Checkpoint Inhibitor Refractory Cancer

 

Download the report to understand which factors are driving Checkpoint Inhibitor Refractory Cancer epidemiology trends @ Checkpoint Inhibitor Refractory Cancer Epidemiology Forecast

 

Checkpoint Inhibitor Refractory Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Checkpoint Inhibitor Refractory Cancer market or expected to get launched during the study period. The analysis covers Checkpoint Inhibitor Refractory Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Checkpoint Inhibitor Refractory Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Checkpoint Inhibitor Refractory Cancer Therapies and Key Companies

  • Tavo + Pembrolizumab: OncoSec Medical
  • CTL-002: CatalYm
  • Bemcentinib + Pembrolizumab: BerGenBio
  • CMP-001 + Nivolumab: Checkmate Pharmaceuticals
  • BCD-100: BIOCAD 
  • Envafolimab: 3D Medicines
  • IBI310: Innovent Biologics
  • Bintrafusp alfa: EMD Serono/Merck
  • CA-170: Aurigene Discovery Technologies
  • CBP501: CanBas Co., Ltd
  • Botensilimab: Agenu
  • FAZ053: Laekna Therapeutics
  • BEBT-260: BeBetter Med
  • SG 12473: Hangzhou Sumgen Biotech
  • HBM-9027: Harbour BioMed       
  • PH-3861: Phio Pharmaceuticals

 

Discover more about therapies set to grab major Checkpoint Inhibitor Refractory Cancer market share @ Checkpoint Inhibitor Refractory Cancer Treatment Market

 

Checkpoint Inhibitor Refractory Cancer Market Strengths

  • The potential benefit of Immune Checkpoint Inhibitors is widespread across most cancer types and an unprecedented number of clinical studies are underway to examine the benefit of these agents.

 

Checkpoint Inhibitor Refractory Cancer Market Opportunities

  • The frequency of immune-related adverse events (irAEs) is dependent on the agents used, exposure time and the administered dose but also on the patient’s intrinsic risk factors.

 

Scope of the Checkpoint Inhibitor Refractory Cancer Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Checkpoint Inhibitor Refractory Cancer Companies: OncoSec Medical, CatalYm, BerGenBio, Checkmate Pharmaceuticals, BIOCAD, 3D Medicines, Innovent Biologics, EMD Serono/Merck, Aurigene Discovery Technologies, CanBas Co., Ltd, Agenu, Laekna Therapeutics, BeBetter Med, Hangzhou Sumgen Biotech, Harbour BioMed, Phio Pharmaceuticals, and others
  • Key Checkpoint Inhibitor Refractory Cancer Therapies: Tavo + Pembrolizumab, CTL-002, Bemcentinib + Pembrolizumab, CMP-001 + Nivolumab, BCD-100, Envafolimab, IBI310, Bintrafusp alfa, CA-170, CBP501, Botensilimab, FAZ053, BEBT-260, SG 12473, HBM-9027, PH-3861, and others
  • Checkpoint Inhibitor Refractory Cancer Therapeutic Assessment: Checkpoint Inhibitor Refractory Cancer current marketed and Checkpoint Inhibitor Refractory Cancer emerging therapies
  • Checkpoint Inhibitor Refractory Cancer Market Dynamics: Checkpoint Inhibitor Refractory Cancer market drivers and Checkpoint Inhibitor Refractory Cancer market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Checkpoint Inhibitor Refractory Cancer Unmet Needs, KOL’s views, Analyst’s views, Checkpoint Inhibitor Refractory Cancer Market Access and Reimbursement 

 

To know more about Checkpoint Inhibitor Refractory Cancer companies working in the treatment market, visit @ Checkpoint Inhibitor Refractory Cancer Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Checkpoint Inhibitor Refractory Cancer Market Report Introduction

2. Executive Summary for Checkpoint Inhibitor Refractory Cancer

3. SWOT analysis of Checkpoint Inhibitor Refractory Cancer

4. Checkpoint Inhibitor Refractory Cancer Patient Share (%) Overview at a Glance

5. Checkpoint Inhibitor Refractory Cancer Market Overview at a Glance

6. Checkpoint Inhibitor Refractory Cancer Disease Background and Overview

7. Checkpoint Inhibitor Refractory Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of Checkpoint Inhibitor Refractory Cancer 

9. Checkpoint Inhibitor Refractory Cancer Current Treatment and Medical Practices

10. Checkpoint Inhibitor Refractory Cancer Unmet Needs

11. Checkpoint Inhibitor Refractory Cancer Emerging Therapies

12. Checkpoint Inhibitor Refractory Cancer Market Outlook

13. Country-Wise Checkpoint Inhibitor Refractory Cancer Market Analysis (2019–2032)

14. Checkpoint Inhibitor Refractory Cancer Market Access and Reimbursement of Therapies

15. Checkpoint Inhibitor Refractory Cancer Market Drivers

16. Checkpoint Inhibitor Refractory Cancer Market Barriers

17.  Checkpoint Inhibitor Refractory Cancer Appendix

18. Checkpoint Inhibitor Refractory Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services


Posted

in

by

Tags: